Periodic booster sessions can also help preserve skin brightness and overall wellness
In contrast, modern GLP-1 receptor agonists and dual incretin agonists have demonstrated clinically meaningful and sustained reductions in body weight, with additional benefits on glycemic control and cardiometabolic risk markers
I'm checking in
These numbers come from the SURMOUNT-1 trial, which enrolled over 2,500 adults with obesity or overweight and tracked outcomes for 72 weeks
Success depends on many factors, including weight history, metabolic risk, appetite, activity, nutrition, sleep, stress, medical conditions, and medication history
(8) A V Schally, X Zhang, R Cai, J M Hare, R Granata, and M Bartoli (2019) Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists Endocrinology, 2019 Jul 1, Volume 160 (Issue 7), Pages 1600-1612